We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Achaogen

News List

Achaogen seeks near-term sale through bankruptcy process fiercebiotech
April 17, 2019
Achaogen is looking to sell its assets and close out its affairs through the bankruptcy process. News of the Chapter 11 filing comes 10 months after Achaogen won FDA approval for its antibiotic Zemdri.
Achaogen wields ax on R&D, C-suite as antibiotic launch gets underway fiercepharma
July 30, 2018
The impact of Achaogen’s narrower-than-expected label for antibiotic Zemdri is now apparent: The biotech has slashed 28% of its staff and all but two R&D programs.
Achaogen Receives Investment from Gates Foundation americanpharmaceuticalreview
May 09, 2017
Achaogen announced it has signed an agreement with the Bill & Melinda Gates Foundation to prevent neonatal sepsis in developing countries through the generation of monoclonal antibodies against gram-negative bacteria.